Powder: -20°C for 3 years | In solvent: -80°C for 1 year
N3-PEG3-vc-PAB-MMAE, a drug-linker conjugate designed for Antibody-Drug Conjugates (ADC), features the integration of monomethyl auristatin E (MMAE), a tubulin inhibitor, via a 3-unit polyethylene glycol (PEG) linker. This compound demonstrates significant antitumor activity.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
100 mg | Inquiry | Inquiry | |
500 mg | Inquiry | Inquiry |
Description | N3-PEG3-vc-PAB-MMAE, a drug-linker conjugate designed for Antibody-Drug Conjugates (ADC), features the integration of monomethyl auristatin E (MMAE), a tubulin inhibitor, via a 3-unit polyethylene glycol (PEG) linker. This compound demonstrates significant antitumor activity. |
In vitro | Monomethyl auristatin E (MMAE; SGD-1010), a synthetic derivative of Dolastatin 10, serves as a powerful mitotic inhibitor via the inhibition of tubulin polymerization. It is extensively utilized as the cytotoxic element in antibody-drug conjugates (ADCs) for the treatment of various cancers. |
Molecular Weight | 1352.66 |
Formula | C67H109N13O16 |
CAS No. | T18473 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
N3-PEG3-vc-PAB-MMAE T18473 Others N3PEG3vcPABMMAE N-3-PEG3-vc-PAB-MMAE N3 PEG3 vc PAB MMAE inhibitor inhibit